The role of the TP53 gene in the development of inherited and sporadic pheochromocytomas and medullary thyroid carcinomas (MTC) has not been clarified because of conflicting reports and limitations in the assays used to detect mutations. To determine the frequency of TP53 alterations in these tumors
Clinical impact of TP53 alterations in adrenocortical carcinomas
β Scribed by Jens Waldmann; Nikolaos Patsalis; Volker Fendrich; Peter Langer; Wolfgang Saeger; Brunhilde Chaloupka; Annette Ramaswamy; Martin Fassnacht; Detlef K. Bartsch; Emily P. Slater
- Book ID
- 106108728
- Publisher
- Springer
- Year
- 2011
- Tongue
- English
- Weight
- 305 KB
- Volume
- 397
- Category
- Article
- ISSN
- 1435-2451
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
In this study we investigated the incidence of mutations and loss of heterozygosity (LOH) of the TP53 gene in DNA samples from paired tumor and adjacent normal tissue from 90 patients with untreated squamous-cell carcinoma of the head and neck. Evidence for TP53 mutations were demonstrated in 53% (4
Thirty-eight WHO grade II astrocytomas and I0 malignant recurrent gliomas in these patients were examined for the presence of TP.53 alterations. Seventeed38 low grade astrocytomas and 6/10 malignant recurrent tumors harbored mutations of the gene detected by SSCP analysis and direct sequencing of PC